^
Association details:
| Biomarker: | MET overexpression + HER-2 overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer
Published date:
09/07/2021
Excerpt:
Volitinib Combined With Trastuzumab Had a Synergistic Activity in Gastric Cancer PDX Models…concomitant overexpression of MET and HER2 in a subset of GC patients, the activity of volitinib combined with trastuzumab was explored in three gastric cancer PDX models with HER2 and MET positive expressions...Volitinib combination with Trastuzumab showed synergistic antitumor effect in both MET and HER2 positive gastric cancer PDX models.
DOI:
https://doi.org/10.3389/fonc.2021.719217
